Safety issues with glucagon ‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials

ConclusionsPresently available data confirm the safety of GLP‐1 receptor agonists for pancreatitis. Conversely, therapy with those drugs is associated with an increased risk of cholelithiasis, which deserves further investigation.

Source: Diabetes, Obesity and Metabolism - June 20, 2017 Category: Endocrinology Authors: Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci Tags: ORIGINAL ARTICLE Source Type: research